Dr Neil Iyengar Emphasizes Importance of Population Health Lens in Oncology at PCOC 2022

Population health brings an important lens to both oncology practice and research, said Neil Iyengar, MD, associate attending physician, breast medical service, Memorial Sloan Kettering Cancer Center.

Population health brings an important lens to both oncology practice and research, said Neil Iyengar, MD, associate attending physician, breast medical service, Memorial Sloan Kettering Cancer Center, at the 2022 meeting of Patient-Centered Oncology Care (PCOC).


Can you elaborate on what it means to bring a population health lens to cancer care?

As an oncologist, when I think about population health, I think that it brings an important lens to how I practice oncology but also the type of research that we do. As an oncologist, we're very much focused on tumor-directed therapy, so oftentimes matching very specific treatments to specific lesions, say genetic lesions within the tumor. But it is helpful to zoom out and think about how host metabolism and other biological processes as well as lifestyle and environment may also influence both cancer risk and response to cancer treatment.

Because there are so many variables in those sorts of aspects of cancer care, population health is very helpful because we can focus on large populations and pull out observations that we may not get from anecdotal, individual experiences. So, when I say that population health helps inform both my practice and the research from a practice lens, population health can be helpful for implementing cancer care models. And from a research lens, population health can be very helpful for asking or understanding what are the right questions to ask. A lot of the questions with regard to lifestyle modification and cancer risk and outcomes were derived from observations of large study cohorts, and we wouldn't have a lot of the lifestyle modification interventions that we have nowadays without the initial observations that were derived from population scientists.

What obesity-related cancers are on the rise, and which populations are most at risk?

There are at least 13 cancers that are related to obesity, and I think that this list is growing as we understand and study more cancers that may be linked to metabolic health. Currently, we define obesity by body mass index [BMI], which is derived from population studies where we use BMI as a tool to understand the general metabolic health of large populations. This is, of course, the weight in kilograms, normalized by the height in meters squared, and this has identified, as I said, at least 13 cancers that are associated with obesity.

We also know that 1 out of 6 male cancer-related deaths and 1 out of 7 female cancer related deaths are related to obesity, so this is a major public health problem. Another issue is that the rates of obesity are on the rise in younger populations and the American Cancer Society put out a report a few years ago showing that the incidence of cancer in younger cohorts, and specifically obesity-related cancers, is on the rise. So we anticipate that the burden of obesity-related cancers worldwide is likely to increase in the coming years.

On top of that, we and others are identifying that BMI or body mass index is not the best tool on the individual level to identify cancers that are related to metabolic health. For example, we've published a report showing that, in women with a normal body mass index, if the body fat levels are above 33%, this is associated with a doubling or more of the risk of developing invasive breast cancer. This is alarming to me because normally we think about people who have a healthy body mass index as not being at risk for obesity-related diseases, including obesity-related cancers.

There's now a growing literature demonstrating that metabolic obesity in normal weight individuals is linked to a number of cardiometabolic disorders, as well as a growing list of cancers. This is a major issue and our interventions need to be matched to identify those individuals that are at risk either because of their body mass index or their underlying metabolic health, and the subsequent intervention be it lifestyle modification should also match, whether it is weight loss or body recomposition by increasing muscle mass and decreasing fat mass. These are the kinds of things that we're currently studying in clinical trials.

Related Videos
Amy Valley, Vice President for Clinical Strategy and Technology Solutions, Cardinal Health
Ben Jones, Vice President of Government Relations and Public Policy, US Oncology Network
Yuqian Liu, PharmD
Screenshot of Adam Colborn, JD
Ben Urick, PharmD, PhD
Manmeet Ahluwalia, MD, MBA.
Nicolas Ferreyros, BA, managing director, The Community Oncology Alliance
Kashyap Patel, MD
Susan Sabo-Wagner, MSN, RN, OCN, Oncology Consultants
Related Content
© 2023 MJH Life Sciences
All rights reserved.